Abbvie ((ABBV)), Pfizer Inc ((PFE)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie and Pfizer are conducting a Phase 1b clinical study titled ‘An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer.’ The study aims to evaluate the efficacy and safety of cofetuzumab pelidotin, a PTK7-targeting antibody drug conjugate, in treating recurrent non-small cell lung cancer (NSCLC) that expresses PTK7.
The study tests the drug cofetuzumab pelidotin, administered intravenously at a dose of 2.8mg/kg every three weeks. This experimental treatment targets PTK7, a protein expressed in certain cancer cells, with the goal of improving patient outcomes in recurrent NSCLC.
This interventional study follows a single-group assignment model without masking, focusing on treatment as its primary purpose. The study does not involve random allocation of participants, and all participants receive the same treatment.
The study began on February 13, 2020, and the latest update was submitted on July 14, 2025. These dates are crucial for tracking the study’s progress and ensuring that it adheres to its timeline.
The outcome of this study could significantly impact AbbVie and Pfizer’s stock performance, as successful results may enhance investor confidence and market positioning in the competitive oncology sector. The collaboration between these industry giants highlights the importance of innovation in cancer treatment.
The study is ongoing, with further details available on the ClinicalTrials portal.